MEDIA_REFRESH_DATA_PRESS_RELEASE
Media
U.S. News Room
Press Releases
Wed Aug 21 00:00:00 GMT-05:00 2019
Updated Clinical Results and New Translational Research Data for Daiichi Sankyo’s ADCs U3-1402 and DS-1062 to be Presented at the 2019 World Conference on Lung Cancer
Download
Mon Aug 12 00:00:00 GMT-05:00 2019
Daiichi Sankyo, Inc. Appoints Simon King as Chief People Officer across U.S. Divisions
Download
Fri Aug 02 00:00:00 GMT-05:00 2019
FDA Approves Daiichi Sankyo’s TURALIO™ (pexidartinib) for the Treatment of Select Patients with TGCT, a Rare and Debilitating Tumor
Download
Fri Jun 21 00:00:00 GMT-05:00 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Download
Tue Jun 18 00:00:00 GMT-05:00 2019
Daiichi Sankyo’s VANFLYTA® Receives Approval in Japan for the Treatment of Relapsed/Refractory FLT3-ITD AML
Download
Sun Jun 02 00:00:00 GMT-05:00 2019
Daiichi Sankyo Presents Preliminary Phase 1 Data for TROP2 Targeting ADC DS-1062 in Patients with Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
Download
Sat Jun 01 00:00:00 GMT-05:00 2019
Daiichi Sankyo’s Pexidartinib Demonstrated Further Improvement with Continued Treatment of Tenosynovial Giant Cell Tumor Patients in New Long-Term Analysis Presented at 2019 ASCO Annual Meeting
Download
Fri May 31 00:00:00 GMT-05:00 2019
Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting
Download
Wed May 15 00:00:00 GMT-05:00 2019
Daiichi Sankyo Data Presentations at 2019 ASCO Annual Meeting Highlight Depth of ADC Pipeline and Promises of Oncology Portfolio
Download